RxDoctor Payments DataLook up a doctor →

Kevin Murphy, MD

Allergy & Immunology · Boys Town, NENPI 1326181249

Payments from drug & device makers

$1,082,676in general payments, 2019–2025

Across 1,056 payments — averaging $1025.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$615K
  • Sanofi$197K
  • Regeneron Healthcare Solutions, Inc.$112K
  • Genentech USA, Inc.$64K
  • Astrazeneca AB$29K
  • Astrazeneca UK Limited$29K
  • plus $36K from 22 others
$24,332in research payments, 2019–2025

Across 11 payments — averaging $2212.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$17K
  • Takeda Pharmaceuticals U.S.A., Inc.$5K
  • Sanofi$2K

What the payments were for

  • Consulting fees$297,90928%
  • Speaking & faculty fees$574,47453%
  • Grants$2,5000%
  • Travel & lodging$183,14217%
  • Food & beverage$22,7942%
  • Education$560%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,082,676 in reported general payments places this provider in the 90th percentile of 21 allergy & immunology providers in Nebraska.

See all allergy & immunology providers in Nebraska

Medicare billing

Part B allowed, 2024
$212,497
Medicare patients
49
Services billed
8,579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab21$77,959
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$21,778
Breo ElliptaFluticasone/Vilanterol36$20,378
SymbicortBudesonide/Formoterol Fumarate17$5,114
QnaslBeclomethasone Dipropionate14$4,858
Incruse ElliptaUmeclidinium Bromide12$4,387
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$1,237
Montelukast Sodium116$878
Wixela InhubFluticasone Propion/Salmeterol12$739
Azelastine Hcl13$493
Albuterol Sulfate HfaAlbuterol Sulfate18$334
Fluticasone Propionate22$302
Prednisone44$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$3,351$46,54476 claims
AstraZenecaSymbicort$614,604$5,11417 claims
Teva Pharmaceuticals USA, Inc.Qnasl$57$4,85814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 allergy & immunology providers in Nebraska.

Other allergy & immunology in Boys Town

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →